Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EPS (Weighted Average and Diluted) (2020 - 2025)

Crinetics Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$1.29 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 48.28% year-over-year to -$1.29; the TTM value through Dec 2025 reached -$4.94, down 33.51%, while the annual FY2025 figure was -$4.95, 34.15% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$1.29 at Crinetics Pharmaceuticals, up from -$1.38 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.7 in Q2 2021 and troughed at -$1.38 in Q3 2025.
  • A 5-year average of -$0.93 and a median of -$0.88 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): rose 4.95% in 2024 and later plummeted 48.28% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.8 in 2021, then decreased by 3.55% to -$0.83 in 2022, then decreased by 6.02% to -$0.88 in 2023, then rose by 1.14% to -$0.87 in 2024, then plummeted by 48.28% to -$1.29 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CRNX at -$1.29 in Q4 2025, -$1.38 in Q3 2025, and -$1.23 in Q2 2025.